Who We Work With
NanoInk is an innovator in the space of pharmaceutical preclinical workflows. Their novel high specificity contrast agent enables researchers to get access to unprecedented level of detail during mouse studies. Not only can the technology image smaller, more clinically relevant tumors, but also image liquid tumors as well as enable later studies. The company is currently at a Series A stage with manufacturing set to begin in early 2026.
FDX has developed a unique manufacturing technology for non-viral delivery vectors. The technology enables manufacturing of highly uniform Lipid, Polymer and other nanoparticles at the scales ranging from Laboratory (10 ml/min) to manufacturing (1000 ml/min) with retention of product quality. The technology has been picked up by major European CDMOs enabling FDX to scale manufacturing of its systems and enter the international pharmaceutical market.
I AM FLUIDCS is commercial stage microencapsulation innovator. Company has developed a unique, in-air Microfluidics technology that enables the manufacture of multiple hundreds of kilograms of highly uniform, complex microbeads with loading more than 50% (w/w). The company’s technology is used across the specialized nutrition, subdermal injectables and Cell and Gene Therapy. The company is currently at the scaling stage and is set to enter pharmaceutical manufacturing industry in early 2026.
Advanced Microfluidics manufacture state-of-art precision fluidic handling equipment. This enables customers to design, develop and implement complex biotech workflow automation equipment for applications such as flow cytometry, cell sorting, API screening and others. AMF can apply its technology to a range of workflows and bridge islands of automation that currently exist in biotech workflows.
SIORA is University of Swansea Spinout. It has developed a unique co-encapsulation technology that enables up to 10x enhancement of efficiency of pharmaceutical R&D workflows. Specifically, the platform enables isolation and co-encapsulation of single cells in well-defined stable droplets for applications in single cell genomics, cell and gene therapies and others. The company is currently in Pre-Seed stage with initial commercial investment set for end of 2025.